Logo

American Heart Association

  2
  0


Final ID: Su1020

Prognostic value of baseline Residual Inflammatory Risk and Residual Triglyceride Risk in patients undergoing Percutaneous Coronary Intervention with optimally managed LDL Cholesterol

Abstract Body (Do not enter title and authors here): Background.
Triglycerides (TG) denote residual triglyceride risk (RTR) while hsCRP indicates residual inflammatory risk (RIR) and both are associated with adverse cardiovascular events.

Question.
In patients undergoing PCI with optimally managed LDL cholesterol (LDL-C), what are the contributions of RTR and RIR to cardiovascular risk?

Aim.
To investigate the associations of RTR and RIR with major adverse cardiac events (MACE) in patients undergoing PCI with optimal LDL-C levels.

Methods.
We evaluated consecutive patients with optimal LDL-C (<70 mg/dL) undergoing PCI at a large tertiary center between 2012 and 2022. Patients were categorized into four subgroups according to baseline TG and hsCRP: (i) No residual risk (hsCRP <2 mg/L + TG <150 mg/dL); (ii) RTR alone (hsCRP <2 mg/L + TG ≥150 mg/dL); (iii) RIR alone (hsCRP >2 mg/L + TG <150 mg/dL); (iv) Combined RIR and RTR (hsCRP ≥2 mg/L+ TG ≥150 mg/dL). Known causes of elevated hsCRP and hsCRP > 10 mg/L were exclusion criteria. The primary outcome was MACE, defined as a composite of all-cause mortality, myocardial infarction, or stroke. A Cox regression model adjusted for multiple covariates was performed to analyze outcomes using patients without residual risk as a reference.

Results.
A total of 9,446 patients were included in the analysis. Of these, 5,339 showed no residual risk, 3,009 RIR only, 555 RTR only, and 543 exhibited a combination of RIR and RTR. After adjustment, RIR was significantly associated with an increased risk of MACE independently of RTR (p<0.001, adj. HR: 1.80, 95% CI: 1.41-2.29 for no RTR and p=0.002, adj. HR: 1.90, 95% CI: 1.27-2.86 for RTR). This was primarily driven by all-cause mortality. Conversely, in patients with only RTR, MACE and all-cause death rates were numerically higher but risk estimates were not statistically significant after adjustment (Figure 1).

Conclusions.
Among patients undergoing PCI with optimally managed LDL-C, RIR was associated with an increased risk of MACE, while RTR did not impact outcomes. HsCRP may be used over TG to stratify the risk for adverse cardiovascular events after PCI.
  • Di Muro, Francesca Maria  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Moreno, Pedro  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Leone, Pier Pasquale  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Krishnamoorthy, Parasuram  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Kini, Annapoorna  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Dangas, George  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Sharma, Samin  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Mehran, Roxana  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Vogel, Birgit  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Sartori, Samantha  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Bay, Benjamin  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Oliva, Angelo  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Gitto, Mauro  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Smith, Kenneth  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Krishnan, Prakash  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Sweeny, Joseph  ( ICAHN SCHOOL OF MEDICINE MT SINAI , New York , New York , United States )
  • Author Disclosures:
    Francesca Maria Di Muro: DO NOT have relevant financial relationships | Pedro Moreno: DO NOT have relevant financial relationships | Pier Pasquale Leone: DO NOT have relevant financial relationships | Parasuram Krishnamoorthy: No Answer | Annapoorna Kini: DO NOT have relevant financial relationships | George Dangas: DO have relevant financial relationships ; Speaker:daiichi sankyo:Past (completed) | Samin Sharma: DO NOT have relevant financial relationships | ROXANA MEHRAN: DO have relevant financial relationships ; Consultant:Abbott, Affluent Medical, Alleviant Medical, Amgen, AstraZeneca, BAIM, Beth Israel Deaconess Medical Center, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CERC, Chiesi, Concept Medical, Daiichi Sankyo, Duke, Faraday, Idorsia, Janssen, MedAlliance, Medscape, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Pi-Cardia, Protembis, RM Global Bioaccess Fund Management, Sanofi:Active (exists now) ; Advisor:AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program):Active (exists now) ; Other (please indicate in the box next to the company name):SCAI (Women in Innovations Committee Member), Faculty CRF, Women as One:Active (exists now) ; Individual Stocks/Stock Options:Elixir Medical, Stel, ControlRad (spouse):Active (exists now) ; Speaker:Affluent Medical, Boehringer Ingelheim, Chiesi USA, Cordis, Esperion Science/Innovative Biopharma, Gaffney Events, Educational Trust, Global Clinical Trial Partners, Ltd., IQVIA, Medscape/WebMD Global, NovoNordisk, PeerView Institute for Medical Education, TERUMO Europe N.V., Radcliffe:Active (exists now) | Birgit Vogel: DO NOT have relevant financial relationships | Samantha Sartori: No Answer | Benjamin Bay: No Answer | ANGELO OLIVA: DO NOT have relevant financial relationships | Mauro Gitto: DO NOT have relevant financial relationships | Kenneth Smith: DO NOT have relevant financial relationships | Prakash Krishnan: No Answer | Joseph Sweeny: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Novel Roles for Lipids and Lipoproteins in Cardiovascular Diseases

Sunday, 11/17/2024 , 03:15PM - 04:15PM

Abstract Poster Session

More abstracts on this topic:
Access to Lipid-Lowering Therapies is Limited by Payer Coverage Restrictions and High Out-of-Pocket Costs on Medicare Prescription Drug Plans

Young Grant, Bansal Kannu, Riello Ralph, Faridi Kamil, Clark Katherine, Desai Nihar

Assessing Trends in Disability-Adjusted Life Years (DALYs) and Age-Adjusted Mortality Rates (AAMR) of Ischemic Heart Disease: A Comparative Analysis of the United States and Global Burden of Disease

Buhadur Ali Muhammad Khan, Shahzaib Muhammad, Qureshi Muhammad Ahmad, Ammar Ur Rahman Mohammad, Munir Luqman, Khalid Amna, Hayat Malik Saad, Shoaib Muhammad Mukarram

More abstracts from these authors:
Validation of a High Bleeding Risk Definition in Cancer Patients Undergoing Percutaneous Coronary Intervention

Gitto Mauro, Leone Pier Pasquale, Di Muro Francesca Maria, Krishnamoorthy Parasuram, Sartori Samantha, Kini Annapoorna, Dangas George, Mehran Roxana, Sharma Samin, Gilhooley Sean, Smith Kenneth, Vogel Birgit, Bay Benjamin, Krishnan Prakash, Sweeny Joseph, Oliva Angelo, Moreno Pedro

Potent P2Y12 inhibitors versus Clopidogrel in Cancer Patients undergoing Percutaneous Coronary Intervention

Gitto Mauro, Moreno Pedro, Di Muro Francesca Maria, Krishnamoorthy Parasuram, Kini Annapoorna, Dangas George, Mehran Roxana, Sharma Samin, Sartori Samantha, Vogel Birgit, Leone Pier Pasquale, Smith Kenneth, Bay Benjamin, Krishnan Prakash, Sweeny Joseph, Oliva Angelo

You have to be authorized to contact abstract author. Please, Login
Not Available